Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

GALT

Galectin Therapeutics Inc

Dec 31 • 04:00PM ET

4.16

+0.08 1.96 %

Healthcare • Biotechnology • USA • NASD

Peers: PFE MRK GILD AMGN ABBV VRTX REGN BIIB NVAX EXEL

| Held by: VTI VXF IWC MEDX QQQS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.59	Insider Own	29.33%	Shs Outstand	64.47M	Perf Week	4.26%
Market Cap	268.24M	Forward P/E	-	EPS next Y	-0.41	Insider Trans	-4.13%	Shs Float	45.57M	Perf Month	-24.50%
Enterprise Value	381.23M	PEG	-	EPS next Q	-0.10	Inst Own	15.94%	Short Float	13.06%	Perf Quarter	-0.48%
Income	-37.44M	P/S	-	EPS this Y	35.53%	Inst Trans	-0.85%	Short Ratio	12.14	Perf Half Y	91.71%
Sales	0.00M	P/B	-	EPS next Y	16.33%	ROA	-178.33%	Short Interest	5.95M	Perf YTD	222.48%
Book/sh	-1.95	P/C	23.26	EPS next 5Y	16.03%	ROE	-	52W High	7.13 -41.65%	Perf Year	261.74%
Cash/sh	0.18	P/FCF	-	EPS past 3/5Y	-13.03% -23.89%	ROIC	-	52W Low	1.07 288.79%	Perf 3Y	240.98%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.90% 11.36%	Perf 5Y	67.07%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	18.82%	Oper. Margin	-	ATR (14)	0.55	Perf 10Y	140.46%
Dividend Ex-Date	-	Quick Ratio	0.09	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	36.45	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.09	EPS Q/Q	28.99%	SMA20	-20.98%	Beta	1.02	Target Price	11.00
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-23.08%	Rel Volume	0.66	Prev Close	4.08
Employees	15	LT Debt/Eq	-	Earnings	Nov 14 BMO	SMA200	21.24%	Avg Volume	489.98K	Price	4.16
IPO	Sep 04, 2002	Option/Short	Yes / Yes	EPS/Sales Surpr.	-18.18% -	Trades		Volume	324,994	Change	1.96%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-17-25	Resumed	H.C. Wainwright	Buy	$6
Aug-13-20	Reiterated	H.C. Wainwright	Buy	$9 → $12
Feb-13-19	Initiated	B. Riley FBR	Buy	$11
Dec-07-17	Reiterated	H.C. Wainwright	Buy	$6 → $10
Nov-28-17	Reiterated	H.C. Wainwright	Buy	$3.50 → $6
Oct-19-17	Initiated	ROTH Capital	Buy
Mar-30-17	Upgrade	H.C. Wainwright	Neutral → Buy	$3.50
Oct-03-16	Downgrade	FBR & Co.	Outperform → Mkt Perform	$12 → $2
Sep-29-16	Downgrade	H.C. Wainwright	Buy → Neutral	$1.50
Sep-28-16	Downgrade	ROTH Capital	Buy → Sell
Mar-28-16	Resumed	H.C. Wainwright	Buy	$8
Sep-21-15	Initiated	H.C. Wainwright	Buy	$7
Aug-01-14	Downgrade	Aegis Capital	Buy → Hold
Jul-30-14	Reiterated	MLV & Co	Buy	$27 → $16
Jul-29-14	Reiterated	MLV & Co	Buy	$27 → $15
Apr-02-14	Reiterated	MLV & Co	Buy	$20 → $27
Feb-10-14	Reiterated	Aegis Capital	Buy	$16 → $32
Jan-09-14	Reiterated	Aegis Capital	Buy	$10 → $16
Dec-03-13	Initiated	MLV & Co	Buy	$20
Aug-19-13	Reiterated	Aegis Capital	Buy	$7 → $10

Show Previous Ratings

Dec-19-25 08:00AM	Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027 (GlobeNewswire) -28.90%
Nov-14-25 08:00AM	Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update (GlobeNewswire)
Nov-10-25 08:00AM	Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting (GlobeNewswire)
Oct-20-25 08:00AM	Galectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference (GlobeNewswire)
Oct-07-25 08:00AM	Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025 (GlobeNewswire) +7.43%
07:21PM	Loading…
Sep-23-25 07:21PM	Galectin Therapeutics Inc. (GALT) Surges on Promising Belapectin Trial Data and Strong Financials (Insider Monkey)
Sep-12-25 12:00PM	Galectin Therapeutics Inc. (GALT) Is Up 7.48% in One Week: What You Should Know (Zacks) -9.60%
Sep-02-25 08:00AM	Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-14-25 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update (GlobeNewswire)
Jul-09-25 08:00AM	Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026 (GlobeNewswire) +7.66%
Jun-18-25 11:19AM	Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going (PR Newswire) +37.66%
Jun-10-25 08:56AM	Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension (GlobeNewswire)
May-15-25 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update (GlobeNewswire)
May-12-25 08:00AM	Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress (GlobeNewswire)
Apr-15-25 08:00AM	Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress (GlobeNewswire)
09:40AM	Loading…
Apr-07-25 09:40AM	Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-31-25 08:00AM	Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update (GlobeNewswire) -19.74%
Feb-18-25 08:00AM	Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial (GlobeNewswire) +8.51%
Jan-10-25 08:00AM	Galectin Therapeutics to Present at the 2025 MASH-TAG Conference (GlobeNewswire)
Dec-20-24 08:00AM	Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH (GlobeNewswire) -48.00%
Dec-09-24 09:35AM	Here's Why Galectin Therapeutics (GALT) is Poised for a Turnaround After Losing -31.83% in 4 Weeks (Zacks) -6.85%
Nov-18-24 08:00AM	Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting (GlobeNewswire)
Nov-14-24 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update (GlobeNewswire) -5.17%
Oct-15-24 08:00AM	Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting (GlobeNewswire)
Sep-30-24 08:00AM	Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference (GlobeNewswire)
Sep-03-24 08:30AM	Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -7.24%
Aug-13-24 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update (GlobeNewswire) +6.64%
Aug-01-24 08:00AM	Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer (GlobeNewswire) -10.60%
Jun-04-24 08:00AM	Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress (GlobeNewswire)
May-15-24 12:53PM	GALT Stock Earnings: Galectin Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +7.75%
08:00AM	Loading…
08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update (GlobeNewswire)
May-13-24 08:00AM	Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference (GlobeNewswire)
Apr-09-24 08:00AM	Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis (GlobeNewswire) +5.35%
Apr-05-24 08:52AM	GALT Stock Earnings: Galectin Therapeutics Meets EPS for Q4 2023 (InvestorPlace) +24.33%
Mar-29-24 09:11AM	Galectin Therapeutics Inc (GALT) Reports 2023 Financial Results and Business Developments (GuruFocus.com)
08:00AM	Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-12-24 08:00AM	Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development (GlobeNewswire)
Nov-13-23 11:11AM	Galectin Therapeutics Inc (GALT) Reports Increased Net Loss in Q3 2023 (GuruFocus.com) -7.14%
08:45AM	UPDATE Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update (GlobeNewswire)
08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update (GlobeNewswire)
Nov-03-23 08:00AM	Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting 2023, Hosted by the AASLD (GlobeNewswire)
Oct-23-23 08:00AM	Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023 (GlobeNewswire)
Oct-12-23 08:00AM	Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors (GlobeNewswire)
Oct-03-23 08:00AM	Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis (GlobeNewswire)
Sep-26-23 08:00AM	Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023 (GlobeNewswire)
Sep-13-23 05:22PM	Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023 (GlobeNewswire) +6.70%
Sep-11-23 09:55AM	Galectin Therapeutics Inc. (GALT)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
08:00AM	Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023 (GlobeNewswire)
Sep-07-23 12:00PM	Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023 (GlobeNewswire) +7.32%
Aug-17-23 12:00PM	What Makes Galectin Therapeutics Inc. (GALT) a New Buy Stock (Zacks) +10.19%
Aug-14-23 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update (GlobeNewswire)
May-18-23 04:37PM	7 Short-Interest Stocks to Target for Explosive Gains (InvestorPlace) +6.38%
May-15-23 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update (GlobeNewswire)
Apr-27-23 08:00AM	Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023 (GlobeNewswire)
Apr-18-23 08:00AM	Galectin Therapeutics Statement Following the Recent 2023 Emerging Topic Conference on NASH Cirrhosis, Sponsored by the American Association for the Study of Liver Diseases (GlobeNewswire)
Mar-30-23 08:00AM	Galectin Therapeutics Reports 2022 Financial Results and Provides Business Update (GlobeNewswire) +5.34%
Mar-16-23 08:00AM	Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis (GlobeNewswire)
Mar-02-23 08:00AM	Galectin Therapeutics Provides Final Randomization Status of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis (GlobeNewswire) +8.29%
Jan-24-23 08:00AM	Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal (GlobeNewswire)
Jan-05-23 08:00AM	Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis (GlobeNewswire) -5.04%
Dec-13-22 09:55AM	Bears are Losing Control Over Galectin Therapeutics Inc. (GALT), Here's Why It's a 'Buy' Now (Zacks)
Nov-29-22 08:00AM	Galectin Therapeutics to Webcast Corporate Update on December 1, 2022 after Annual Meeting of Stockholders (GlobeNewswire)
Nov-28-22 08:00AM	Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit (GlobeNewswire)
Nov-14-22 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Business Update (GlobeNewswire) +5.56%
Nov-01-22 08:00AM	Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting 2022, Hosted by the AASLD (GlobeNewswire)
Oct-14-22 08:00AM	Galectin Therapeutics to Present in Upcoming Conferences (GlobeNewswire) +5.19%
Oct-12-22 08:00AM	Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer (GlobeNewswire)
Oct-06-22 08:00AM	Galectin Therapeutics Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis (GlobeNewswire)
Sep-08-22 08:00AM	Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference September 13, 2022 (GlobeNewswire) +5.65%
Aug-15-22 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2022 and Provides Business Update (GlobeNewswire) +5.31%
Jul-26-22 08:00AM	Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024 (GlobeNewswire)
Jun-21-22 08:00AM	Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress 2022 (GlobeNewswire)
May-23-22 08:00AM	Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress (GlobeNewswire)
May-16-22 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update (GlobeNewswire) -7.35%
May-11-22 11:20AM	Catalyst Pharmaceuticals (CPRX) Q1 Earnings Miss, Revenues Up Y/Y (Zacks) -6.47%
May-03-22 08:30AM	Nano Dimensions Preliminary Q1/2022 Revenues: Approximately $10.5 Million (GlobeNewswire)
Apr-15-22 07:20AM	Is Galectin Therapeutics Inc. (NASDAQ:GALT) Popular Amongst Insiders? (Simply Wall St.)
Apr-14-22 08:00AM	Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis (GlobeNewswire) +10.13%
Mar-31-22 08:00AM	Galectin Therapeutics Reports 2021 Financial Results and Provides Business Update (GlobeNewswire) -5.85%
Jan-06-22 08:00AM	Galectin Therapeutics to Present at the H.C. Wainwright BioConnect Conference (GlobeNewswire)
Dec-21-21 08:00AM	Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. Uihlein (GlobeNewswire)
Dec-13-21 08:00AM	Galectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial and Outlines Strategy for Potential Phase 2 Cancer Immunotherapy Trial at Annual Meeting (GlobeNewswire)
Nov-15-21 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2021, and Provides Business Update (GlobeNewswire)
Nov-05-21 04:24PM	UPDATE Galectin Therapeutics to Present Six Scientific Abstracts at The Liver Meeting 2021, Hosted by the AASLD (GlobeNewswire)
Oct-27-21 08:00AM	Galectin Pharmaceuticals to Present Six Scientific Abstracts at The Liver Meeting 2021, Hosted by the AASLD (GlobeNewswire)
Oct-05-21 03:39PM	UPDATE: Galectin Therapeutics to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021 (GlobeNewswire)
01:55PM	Galectin Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Sep-21-21 08:00AM	Galectin Therapeutics Announces $20 Million Convertible Debt Financing from Its Chairman, Richard E. Uihlein (GlobeNewswire)
Sep-09-21 09:00AM	Galectin Therapeutics, Inc. to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-30-21 08:00AM	Galectin Therapeutics Strengthens Leadership Team with Strategic Hires to Advance Programs in Cancer Immunotherapy and NASH Cirrhosis (GlobeNewswire)
Aug-16-21 09:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2021, and Provides Business Update (GlobeNewswire)
Jul-30-21 04:28AM	Here's What Galectin Therapeutics Inc.'s (NASDAQ:GALT) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Jul-09-21 09:25AM	Galectin Therapeutics Stock Surges After Robust Data From Belapectin/Keytruda Combo In Melanoma, Head & Neck Cancer (Benzinga) +25.00%
08:00AM	Galectin Therapeutics Announces Positive Top-Line Results from a Phase 1b Clinical Trial Extension of Belapectin in Combination with KEYTRUDA® in Advanced Metastatic Melanoma and Head and Neck Cancer (GlobeNewswire)
06:29AM	Galectin Therapeutics Soars on Positive Melanoma Treatment Data (TheStreet.com)
Jun-13-21 11:23PM	Is Galectin Therapeutics Inc. (GALT) A Good Stock To Buy? (Insider Monkey)
May-17-21 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2021, and Provides Business Update (GlobeNewswire)
Apr-27-21 09:28AM	Galectin Therapeutics to Present at 4th Global NASH Congress (GlobeNewswire)
Apr-19-21 08:00AM	World-Renowned Neurosurgeon Dr. Ben Carson, Sr. Joins Galectin Therapeutics as Special Consultant to Accelerate and Enhance Development of Companys Galectin-3 Inhibitor, Belapectin (GlobeNewswire) +26.94%
Apr-15-21 09:00AM	Company News for Apr 15, 2021 (Zacks) -5.51%

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jamil Khurram	Officer	Dec 31 '25	Proposed Sale	4.10	8,125	33,313		Dec 31 04:08 PM
ELDRED KARY	Director	Dec 23 '25	Buy	3.73	700	2,611	65,382	Dec 23 01:17 PM
FREEMAN KEVIN D	Director	Dec 23 '25	Buy	3.55	5,500	19,514	55,269	Dec 23 11:29 AM
ELDRED KARY	Director	Dec 23 '25	Buy	3.73	700	2,611	65,382	Dec 23 11:28 AM
LEWIS JOEL	President and CEO	Dec 17 '25	Option Exercise	2.86	7,829	22,391	840,421	Dec 19 04:08 PM
LEWIS JOEL	President and CEO	Dec 17 '25	Sale	7.06	7,829	55,241	832,592	Dec 19 04:08 PM
Jamil Khurram	Chief Medical Officer	Dec 17 '25	Option Exercise	2.37	14,963	35,469	8,500	Dec 19 04:06 PM
Jamil Khurram	Chief Medical Officer	Dec 17 '25	Sale	7.04	19,442	136,872	0	Dec 19 04:06 PM
Shlevin Harold H.	Director	Dec 17 '25	Option Exercise	1.98	20,000	39,600	31,206	Dec 19 04:05 PM
Shlevin Harold H.	Director	Dec 17 '25	Sale	7.04	24,499	172,424	6,500	Dec 19 04:05 PM
10X Fund, L.P.	10% Owner	Dec 16 '25	Sale	6.66	30,681	204,335	5,614,457	Dec 18 10:34 AM
HAROLD SHLEVIN	DIRECTOR	Dec 17 '25	Proposed Sale	6.97	24,706	172,223		Dec 17 04:44 PM
Jamil Khurram	Officer	Dec 17 '25	Proposed Sale	7.04	21,479	151,212		Dec 17 04:33 PM
LEWIS JOEL	Officer	Dec 17 '25	Proposed Sale	7.06	40,000	282,244		Dec 17 04:29 PM
Shlevin Harold H.	Director	Dec 12 '25	Option Exercise	4.16	19,793	82,339	30,999	Dec 16 04:22 PM
Shlevin Harold H.	Director	Dec 15 '25	Option Exercise	4.16	8,417	35,015	19,623	Dec 16 04:22 PM
Shlevin Harold H.	Director	Dec 12 '25	Sale	6.27	19,793	124,181	11,206	Dec 16 04:22 PM
Shlevin Harold H.	Director	Dec 15 '25	Sale	6.30	8,417	53,027	11,206	Dec 16 04:22 PM
HAROLD SHLEVIN	DIRECTOR	Dec 15 '25	Proposed Sale	6.24	8,417	52,542		Dec 15 04:32 PM
HAROLD SHLEVIN	DIRECTOR	Dec 12 '25	Proposed Sale	6.21	19,793	122,993		Dec 12 05:27 PM
Shlevin Harold H.	Director	Dec 08 '25	Option Exercise	2.07	155,000	320,950	46,206	Dec 10 08:15 AM
Shlevin Harold H.	Director	Dec 09 '25	Option Exercise	4.16	16,790	69,846	27,996	Dec 10 08:15 AM
Shlevin Harold H.	Director	Dec 08 '25	Sale	5.98	159,000	950,105	11,206	Dec 10 08:15 AM
Shlevin Harold H.	Director	Dec 09 '25	Sale	6.27	16,790	105,206	11,206	Dec 10 08:15 AM
HAROLD SHLEVIN	DIRECTOR	Dec 09 '25	Proposed Sale	6.21	16,790	104,198		Dec 09 04:36 PM
HAROLD SHLEVIN	DIRECTOR	Dec 08 '25	Proposed Sale	6.02	159,000	957,180		Dec 08 07:40 PM
10X Fund, L.P.	10% Owner	Dec 03 '25	Sale	5.73	120,000	687,600	5,682,207	Dec 04 04:57 PM
10X Fund, L.P.	10% Owner	Dec 02 '25	Sale	5.47	30,000	164,100	5,802,207	Dec 04 04:57 PM
LEWIS JOEL	President and CEO	Nov 17 '25	Option Exercise	2.39	15,680	37,475	848,272	Nov 19 04:01 PM
LEWIS JOEL	President and CEO	Nov 18 '25	Option Exercise	2.39	6,783	16,211	839,375	Nov 19 04:01 PM
LEWIS JOEL	President and CEO	Nov 17 '25	Sale	6.04	15,680	94,643	832,592	Nov 19 04:01 PM
LEWIS JOEL	President and CEO	Nov 18 '25	Sale	6.15	6,783	41,723	832,592	Nov 19 04:01 PM
CALLICUTT JACK W	Chief Financial Officer	Nov 18 '25	Option Exercise	1.64	46,310	75,851	35,714	Nov 19 04:01 PM
CALLICUTT JACK W	Chief Financial Officer	Nov 17 '25	Option Exercise	1.38	31,610	43,706	27,315	Nov 19 04:01 PM
CALLICUTT JACK W	Chief Financial Officer	Nov 18 '25	Sale	6.22	46,310	288,187	7,614	Nov 19 04:01 PM
CALLICUTT JACK W	Chief Financial Officer	Nov 17 '25	Sale	6.03	31,610	190,662	7,614	Nov 19 04:01 PM
Jamil Khurram	Chief Medical Officer	Nov 13 '25	Option Exercise	2.17	99,250	215,038	45,979	Nov 14 04:02 PM
Jamil Khurram	Chief Medical Officer	Nov 13 '25	Sale	5.47	121,117	662,510	4,479	Nov 14 04:02 PM
Jamil Khurram	Officer	Nov 13 '25	Proposed Sale	5.45	121,117	660,088		Nov 13 05:03 PM
10X Fund, L.P.	10% Owner	Nov 11 '25	Sale	5.25	40,000	210,000	5,832,207	Nov 12 04:33 PM
LEWIS JOEL	President and CEO	Nov 10 '25	Option Exercise	2.39	1,867	4,462	834,459	Nov 12 04:01 PM
LEWIS JOEL	President and CEO	Nov 10 '25	Sale	6.03	1,867	11,252	832,592	Nov 12 04:01 PM
CALLICUTT JACK W	Chief Financial Officer	Nov 10 '25	Option Exercise	1.46	5,291	7,717	9,694	Nov 12 04:01 PM
CALLICUTT JACK W	Chief Financial Officer	Nov 10 '25	Sale	6.03	5,291	31,884	7,614	Nov 12 04:01 PM
LEWIS JOEL	President and CEO	Nov 05 '25	Option Exercise	2.39	200	478	832,792	Nov 07 04:09 PM
LEWIS JOEL	President and CEO	Nov 05 '25	Sale	6.00	200	1,200	832,592	Nov 07 04:09 PM
CALLICUTT JACK W	Chief Financial Officer	Nov 05 '25	Option Exercise	1.60	600	962	7,814	Nov 07 04:07 PM
CALLICUTT JACK W	Chief Financial Officer	Nov 05 '25	Sale	6.00	600	3,600	7,614	Nov 07 04:07 PM
LEWIS JOEL	President and CEO	Nov 04 '25	Option Exercise	2.39	14,420	34,464	847,012	Nov 05 04:06 PM
LEWIS JOEL	President and CEO	Nov 03 '25	Option Exercise	2.39	1,300	3,107	833,892	Nov 05 04:06 PM
LEWIS JOEL	President and CEO	Nov 04 '25	Sale	6.07	14,420	87,529	832,592	Nov 05 04:06 PM
LEWIS JOEL	President and CEO	Nov 03 '25	Sale	6.01	1,300	7,813	832,592	Nov 05 04:06 PM
CALLICUTT JACK W	Chief Financial Officer	Nov 04 '25	Option Exercise	1.61	28,629	46,085	18,355	Nov 05 04:06 PM
CALLICUTT JACK W	Chief Financial Officer	Nov 03 '25	Option Exercise	1.61	3,810	6,123	8,914	Nov 05 04:06 PM
CALLICUTT JACK W	Chief Financial Officer	Nov 04 '25	Sale	6.07	28,629	173,778	7,614	Nov 05 04:06 PM
CALLICUTT JACK W	Chief Financial Officer	Nov 03 '25	Sale	6.01	3,810	22,898	7,614	Nov 05 04:06 PM
10X Fund, L.P.	10% Owner	Oct 22 '25	Sale	4.94	50,000	246,800	5,872,207	Oct 24 08:18 PM
CALLICUTT JACK W	Chief Financial Officer	Sep 12 '25	Option Exercise	1.37	8,706	11,927	16,320	Sep 15 12:45 PM
CALLICUTT JACK W	Chief Financial Officer	Sep 12 '25	Sale	6.44	8,706	56,054	7,614	Sep 15 12:45 PM
LEWIS JOEL	President and CEO	Sep 12 '25	Option Exercise	2.39	14,000	33,460	846,592	Sep 15 12:45 PM
LEWIS JOEL	President and CEO	Sep 12 '25	Sale	6.36	14,000	89,048	832,592	Sep 15 12:45 PM
LEWIS JOEL	Officer	Sep 12 '25	Proposed Sale	6.36	54,250	345,063		Sep 12 04:38 PM
CALLICUTT JACK W	Officer	Sep 12 '25	Proposed Sale	6.44	141,206	909,155		Sep 12 04:37 PM
ELDRED KARY	Director	Jul 21 '25	Buy	2.92	1,000	2,925	64,682	Jul 22 07:36 AM
FREEMAN KEVIN D	Director	Jul 17 '25	Buy	2.90	5,000	14,495	49,769	Jul 18 10:38 AM
CZIRR JAMES C	10% Owner	Jun 06 '25	Option Exercise	2.16	323,125	699,344	1,045,541	Jun 11 06:25 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GALT

Galectin Therapeutics Inc

Upgrade your FINVIZ experience